- USFDA lifts import alert on Aurobindo Pharma's antibiotics Hyderabad facilityBSE Sensex rises 158 pts, SBI shares limit gains, ITC Ltd, Sun Pharmaceuticals shares leadAurobindo Pharma surges 12 pct on Q1 profitDespite Ranbaxy Laboratories, others, India's USFDA record better than most others'
Aurobindo Pharma today said its consolidated net profit rose 5.7 per cent to Rs 235 crore for the second quarter ended September 30, 2013.
The Hyderabad-based firm posted a profit after tax of Rs 222.4 crore during July-September last year.
The company's total income from operations increased by 27.6 per cent to Rs 1,913.9 crore in the second quarter (Q2) of this fiscal compared to Rs 1,500.4 crore in the same period last fiscal, Aurobindo Pharma said in a statement.
"The integrated business in generic formulations is auguring well to drive the operating performance of the company. We are also investing in specific new, differentiated products offerings such as Oncology, Hormones, Peptides and OTC business which we believe will complement our business in the coming years," Aurobindo Pharma Ltd Managing Director N Govindarajan said.
Shares of Aurobindo Pharma closed at Rs 238.35 apiece, down 1.71 per cent on the BSE.